Fundraising FoxCingulate Therapeutics
Morristown, US · Delaware LLC · 1 known investors
Find your way into Cingulate Therapeutics
Sign up to see every warm intro you have to Cingulate Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cingulate Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
LG
Louis George Van HornExecutive
RR
Raul R SilvaChief Science OfficerRaul Silva is Chief Science Officer at Cingulate Therapeutics. A child and adolescent psychiatrist with board certification in general, child and adolescent psychiatry, he previously held faculty positions at New York University School of Medicine as Associate Professor and Vice Chairman, served as Executive Director of Rockland Children's Psychiatric Center, and worked as Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, with research and publication experience in psychopharmacology and the effects of stress and trauma on children and adolescents.
CS
Craig Steven GilgallonExecutive
Board
PJ
Patrick J GallagherBoard director
AB
Arthur B StraughnBoard director
Investors · 1
Also in the syndicate · 1
Werth Family Investment Associates
Reported raises · per SEC filings
Form D private placements$33M disclosed across 2 of 3 rounds · 2013–2018
▶$26.2MraisedJun 2020 · 203 investors · PharmaceuticalsRule 506(b)
▶$26.2MraisedJun 2020 · 203 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew N BramsExecutive Officer, Director
- Jeff ConroyDirector
- Louis George Van HornExecutive Officer
- Craig Steven GilgallonExecutive Officer
- Laurie A MyersExecutive Officer
- Raul R SilvaExecutive Officer
- Patrick J GallagherDirector
- Jeff HargrovesDirector
- Arthur B StraughnDirector
- Shane J SchafferExecutive Officer, Director
- Peter WerthDirector
- Amount sold
- $26.2M
- Minimum investment
- $100K
- Proceeds to insiders
- $1.3M
- First sale
- Nov 2013
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$6.8MraisedJan 2018 · 116 investors · PharmaceuticalsRule 506(b)
▶$6.8MraisedJan 2018 · 116 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Louis George Van HornExecutive Officer
- Raul R SilvaExecutive Officer
- Laurie A MyersExecutive Officer, Director
- Matthew N BramsExecutive Officer, Director
- Shane j SchafferExecutive Officer, Director
- Patrick J GallagherDirector
- Craig Steven GilgallonExecutive Officer
- Arthur B StraughnDirector
- Amount sold
- $6.8M
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Nov 2013
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Cingulate Therapeutics?
- Cingulate Therapeutics was founded by Shane j Schaffer.
- How much funding has Cingulate Therapeutics raised?
- Cingulate Therapeutics has disclosed $33M raised across 2 of its 3 known rounds.
- Where is Cingulate Therapeutics headquartered?
- Cingulate Therapeutics is headquartered in Morristown, US.